Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ1,00
KB0,00
PKN83,983,942,92
Msft152,55152,560,59
Nokia3,22853,2322,64
IBM135,27135,291,14
Daimler AG50,1350,141,28
PFE38,4938,50,73
12.12.2019 17:19:57
Indexy online
AD Index online
select
AD Index online
 

  • 12.12.2019 17:19:38
Novartis AG Depository Receipt (NVS, NY Consolidated)
Poslední obchod Změna (%) Změna (USD) Objem obchodů (ks)
92,70 -0,37 -0,34 543 142
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 12.12.2019
Popis společnosti
Obecné informace
Název společnostiNovartis AG (ADR)
TickerNVS
Kmenové akcie:ADR
RICNVS
ISINUS66987V1098
Poslední známé roční výsledky31.12.2018
Poslední známé čtvrtletní výsledky30.09.2019
Počet zaměstnanců k 30.09.2019 109 000
Akcie v oběhu k 25.10.20192 527 374 820
Počet akcionářů k 31.12.2018 162 960
MěnaUSD
Kontaktní informace
UliceLichtstrasse 35
MěstoBASEL
PSČ4056
ZeměSwitzerland
Kontatní osoba 
Funkce kontaktní osoby 
Telefon41 613 241 111
Fax41613247826

Business Summary: Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company's segments include Innovative Medicines, Sandoz, Alcon and Corporate activities. Innovative Medicines researches, develops, manufactures, distributes and sells patented prescription medicines to develop health outcomes for patients and healthcare providers. Sandoz develops, manufactures, distributes and sells prescription medicines, as well as pharmaceutical active substances that are not protected by valid and enforceable third-party patents. Alcon researches, develops, manufactures, distributes and sells eye care products. Alcon is a provider of eye care with product offerings in eye care devices and vision care. The Company's range of products includes pharmaceuticals and oncology medicines, generic and biosimilar medicines, and eye care devices.
Financial Summary: BRIEF: For the nine months ended 30 September 2019, Novartis AG (ADR) revenues increased 5% to $35.91B. Net income before extraordinary items decreased 48% to $6.02B. Revenues reflect Innovative Medicines segment increase of 7% to $27.79B, US segment increase of 11% to $11.94B, Europe segment increase of 3% to $13.35B, Asia / Africa / Australasia segment increase of 3% to $7.22B.
Odvětvová klasifikace
TRBC2012Pharmaceuticals - NEC
RBSS2004Pharmaceuticals - Diversified
MGINDUSTRYMajor Drugs
MGSECTORHealthcare
NAICSPharmaceutical Preparation Manufacturing
NAICSBiological Product (except Diagnostic) Manufacturing
NAICSMedicinal and Botanical Manufacturing
NAICSSurgical and Medical Instrument Manufacturing
NAICSOphthalmic Goods Manufacturing
NAICSResearch and Development in the Physical, Engineering, and Life Sciences
NAICSOffices of Other Holding Companies
SICPharmaceutical Preparations
SICBiological Prod's Not Diagnostic
SICMedicinals And Botanicals
SICSurgical And Medical Instruments
SICOphthalmic Goods
SICCommercial Physical Research
SICHolding Companies, Nec



  • Poslední aktualizace: 12.12.2019
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
Chief Executive Officer, Member of the Executive CommitteeVasant Narasimhan4301.02.201801.02.2016
Chief Financial Officer, Member of the Executive CommitteeHarry Kirsch5401.05.201301.05.2013
Chief People & Organization Officer, Member of the Executive CommitteeSteven Baert4526.02.201426.02.2014
Global Head of Novartis Technical Operations, Member of the Executive CommitteeSteffen Lang5201.04.201801.04.2018
Chief Ethics, Risk and Compliance Officer, Member of the Executive CommitteeKlaus Moosmayer5101.12.201801.12.2018
Group General Counsel, Member of the Executive CommitteeShannon Klinger4801.06.201801.04.2018
Chief Digital Officer, Member of the Executive CommitteeBertrand Bodson4401.04.201801.01.2018
President of the Novartis Institutes for BioMedical Research (NIBR), Member of the Executive CommitteeJames Bradner4701.03.201601.03.2016
Chief Executive Officer of Sandoz, Member of the Executive CommitteeRichard Saynor5215.07.201915.07.2019
CEO Novartis Oncology, Member of the Executive CommitteeSusanne Schaffert5201.01.201901.01.2019